Your Messages Inbox
Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
See Latest ArticlesCertolizumab Pegol: In Rheumatoid Arthritis
BioDrugs, 11/10/09
Duggan ST et al. – Certolizumab pegol is a PEGylated humanized Fab? monoclonal antibody that targets and neutralizes both membrane–bound and soluble tumor necrosis factor (TNF)–alpha, preventing inflammation and consequently the destruction of cartilage and bone. Certolizumab pegol has a relatively long elimination half–life of ?2 weeks, allowing subcutaneous administration once every 2 or 4 weeks...In patients with active rheumatoid arthritis who had previously failed to respond to treatment with >=1 disease–modifying anti–rheumatic drug, certolizumab pegol 400 mg every 4 weeks as monotherapy effectively improved ACR responses at all measured timepoints up to 24 weeks, according to data from the randomized, phase III FAST4WARD trial. Certolizumab pegol was generally well tolerated in combination with methotrexate or as monotherapy in phase III trials in patients with rheumatoid arthritis, with most adverse events being of mild to moderate intensity. Infections were the most frequently reported adverse events.
Related Articles
Effect of certolizumab pegol with methotrexate on home and work place productivity and social activities in patients with active rheumatoid arthritis
Arthritis Care and Research, 11/02/09
Relevance Score: 88%
Rapid and sustained improvements in health-related quality of life, fatigue, and other patient-reported outcomes in rheumatoid arthritis patients treated with certolizumab pegol plus methotrexate over 1 year: Results from the RAPID 1 randomized controlled trial
Arthritis Research & Therapy, 11/16/09
Relevance Score: 87%
Efficacy of roxithromycin in adult patients with rheumatoid arthritis who had not received disease-modifying antirheumatic drugs: A 3-month, randomized, double-blind, placebo-controlled trial
Clinical Therapeutics, 10/15/09
Relevance Score: 71%
Assistive technology for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 70%
Abatacept for rheumatoid arthritis
Cochrane Reviews, 10/09/09
Relevance Score: 69%
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Treatment with alpha-lipoic acid reduces asymmetric dimethylarginine in patients with type 2 diabetes mellitus
Translational Research, The Journal of Laboratory and Clinical Medicine, 12/11/09
Emerging technologies in the delivery of erythropoietin for therapeutics
Medicinal Research Reviews, 12/11/09
Drug treatment of prehypertension: Not now, not ever
Blood Pressure, 12/11/09
Today in Orthopedic/Physical Med...keeping you current
Receive free subspecialty "5-minute updates" via email
Calcium phosphate cement to prevent collapse in avascular necrosis of the femoral head
Medical Hypotheses, 12/11/09
Sit-to-Stand Movement as a Performance-Based Measure for Patients With Total Knee Arthroplasty: A Clinical Trial
Physical Therapy, 12/11/09
Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: Systematic review and meta-analysis
Osteoporosis International, 12/11/09
Today in Rheumatology...keeping you current
Receive free subspecialty "5-minute updates" via email
Criterion Contamination of Depression Scales in Patients with Rheumatoid Arthritis: The Need for Interpretation of Patient Questionnaires (as All Clinical Measures) in the Context of All Information About the Patient
Rheumatic Disease Clinics of North America, 12/11/09
The HAQ Compared with the MDHAQ: Keep It Simple, Stupid (KISS), with Feasibility and Clinical Value as Primary Criteria for Patient Questionnaires in Usual Clinical Care
Rheumatic Disease Clinics of North America, 12/11/09
A survey of European and Canadian rheumatologists regarding the treatment of patients with ankylosing spondylitis and extra-articular manifestations
Clinical Rheumatology, 12/11/09
Sponsor
Article Search
Sponsor
Sponsor